AI-enabled drug transactions increasingly turn on more than patents and scientific merit. This article examines data provenance, IP ownership, collaboration terms, and model dependencies that can affect diligence, valuation, and deal readiness.

In AI-enabled drug discovery, enterprise value depends on more than the pipeline. Data ownership, licensing terms, model improvements, and platform dependencies can shape IP strategy, diligence, and commercialization.

AI has accelerated drug discovery, but it has also shortened the window of competitive advantage. This article explores why patent strategy must evolve beyond protecting individual molecules to safeguarding the platforms, data, and infrastructure that create long-term business value.